<DOC>
	<DOCNO>NCT02169609</DOCNO>
	<brief_summary>The purpose study evaluate safety triple COG schema monoclonal antibody Dinutuximab + cytokine ( GM-CSF IL2 ) isotretinoin ( 13-cis-retinoic acid , RA ) patient high-risk neuroblastoma .</brief_summary>
	<brief_title>Safety Study Dinutuximab Combined With Immunotherapy Treat Neuroblastoma</brief_title>
	<detailed_description>Assess toxicity safety subcutaneous GM-CSF iv IL-2 enhance Dinutuximab-mediated ablation Bone Marrow ( BM ) disease patient high-risk neuroblastoma achieve Complete Response Very Good Partial Response macroscopic disease investigator institution . Assess response minimal residual disease ( MRD ) anti-GD2 monoclonal antibody Dinutuximab combine granulocyte-macrophage colony stimulate factor ( GM-CSF ) IL-2 patient high-risk neuroblastoma ( NB ) . More precisely , apply real-time quantitative RT-PCR test hypothesis minimal residual disease content BM first treatment dinutuximab/GM-CSF significant prognostic impact relapse-free survival .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>1 . Diagnosis neuroblastoma define international criterion histopathology bone marrow metastasis . Patients age must less 18 year time initial diagnosis . 2 . Neuroblastoma , define riskrelated treatment guideline International Neuroblastoma Staging System , stage 4 ( age ) without ( &gt; 18 month ) MYCNamplification , MYCNamplified neuroblastoma stage 1 , highrisk neuroblastoma define base 3gene molecular profile develop institution ( Garcia I , et al . CCR 2012 ) . Group 1 patient neuroblastoma ( define ) resistant standard therapy , evidence incomplete response bone marrow , MIBGavid soft tissue bone tumor progressive disease . Group 2 patient evidence measurable disease 3 Patients must Lansky Karnofsky Performance Scale score &gt; 50 % patient must life expectancy &gt; 2 month . 4 Preenrollment tumor survey : Prior enrollment determination residual disease must Performed ( Tumor image study include CT MRI , MIBG scan , bone marrow aspiration &amp; biopsy , blood bone marrow sample ) . This disease assessment require eligibility . 5 Patients must adequate organ function time registration : Hematological : Total absolute phagocyte count ( APC = neutrophils + monocyte ) least 1000/microL Renal : Adequate Renal Function Defined As : Creatinine clearance radioisotope GFR &gt; 70 mL/min/1.73 m2 serum creatinine base age/gender . Hepatic total bilirubin &lt; 1.5 x normal , SGPT ( ALT ) &lt; 5 x normal . Venoocclusive disease , present , stable improving . Cardiac shorten fraction &gt; 30 % echocardiogram , shorten fraction abnormal , ejection fraction &gt; 55 % gate radionuclide study . Pulmonary FEV1 FVC &gt; 60 % predict pulmonary function test . For child unable PFTs , evidence dyspnea rest , exercise intolerance . Central nervous system Patients seizure disorder may enrol anticonvulsant wellcontrolled . CNS toxicity &lt; Grade 2 . 6 Females childbearing potential must negative pregnancy test . Patients childbearing potential must agree use effective birth control method . Female patient lactate must agree stop breastfeeding . 7 Signed inform consent indicate awareness investigational nature program . 1 . Existing severe major organ dysfunction , i.e. , renal. , cardiac , hepatic , neurologic , pulmonary , gastrointestinal toxicity â‰¥ grade 3 . 2 . Progressive disease MIBGavid soft tissue/bone tumor . 3 . Active lifethreatening infection . 4 . Inability comply protocol requirement . 5 . Patient eligible SIOP HRNB01 protocol ( = newly diagnose highrisk neuroblastoma patient center SIOP protocol open enrollment ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Dinutuximab</keyword>
</DOC>